




FIG. 1A

2/78




FIG. 1B




FIG. 1C




FIG. 1D

5/78





FIG. 1E

6/78

**FIG. 1F**

7/78




FIG. 1G




FIG. 1H




FIG. 1I




FIG. 1J




FIG. 1K




FIG. 2A




FIG. 2B

13/78




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 2F





FIG. 2G

18/78

**FIG. 2H**




FIG. 2I




FIG. 2J




FIG. 3A




FIG. 3B






FIG. 3C

24/78



YAPhigh vs YAPlow
odds ratio for caspase 3/7 positivity
0.26, $p < 0.0001$

FIG. 3D




FIG. 3E




FIG. 3F




FIG. 3G




FIG. 3H

27/78




FIG. 3I

28/78




FIG. 3J




FIG. 4A





FIG. 4B

30/78



**in vitro* showing Vehicle/DSMO and Osimertinib/Tramentinib from left to right respectively; *in vivo* showing Vehicle/DSMO, Osimertinib, and Osimertinib/Tramentinib from left to right respectively

FIG. 4C




FIG. 4D





FIG. 4E



*PC-9 xenograft graphs show Vehicle, Osimertinib, and Osimertinib+trametinib from left to right respectively; GEMM graphs show Vehicle and Osimertinib from left to right respectively.

FIG. 4F




FIG. 4G




FIG. 4H




FIG. 4I




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D

PC-9 HA-BMF cells



FIG. 5E




FIG. 5F




FIG. 5G




FIG. 5H




FIG. 5I





FIG. 6A



*PC-9, HCC827, HCC4006, and DFCI243 compounds show SNAI1 (SNAIL), SNAI2 (SLUG), TWIST1, TWIST2, ZEB1, and ZEB2 from left to right respectively.

FIG. 6B




FIG. 6C

41/78




FIG. 6D




FIG. 6E




FIG. 6F




FIG. 6G




FIG. 6H




FIG. 6I







FIG. 7A

45/78

**FIG. 7B****FIG. 7C**




FIG. 7D




FIG. 7E

PC-9 YAP reporter cells




FIG. 7F

PC-9




FIG. 7G




FIG. 7H





FIG. 7I



HCC4006

FIG. 8A






FIG. 8B


51/78

**FIG. 8C**

52/78

**FIG. 9A**

53/78

**FIG. 9B**




FIG. 10A




FIG. 10B




FIG. 10C

57/78




FIG. 10D




FIG. 11A





FIG. 11B




FIG. 11C

Drug	Target	concentration used (μM)
ZSTK474	PI3K	1.0
BEZ235	PI3K/mTOR	0.1
AZD2014	mTOR	0.1
ruxolitinib	JAK1/2	1.0
Saracatinib	Src family kinases	1.0
BMS-345541	Ikk	1.0
sotrastaurin	PKC	1.0
Galunisertib (LY2157299)	TGF-β receptor	1.0
gefitinib	EGFR	1.0
crizotinib	MET	1.0
displatin	DNA	1.0
XAV939	Tankyrase	1.0

DAPT (GSI IX)	Notch (γ-secretase)	5.0
LY451039	Notch (γ-secretase)	1.0

FIG. 11D




FIG. 11E

63/78




FIG. 12




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 14A

FIG. 14B

FIG. 14C




FIG. 14D






FIG. 14E






FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D



FIG. 15E




FIG. 15F




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D

78/78

NCI-H226 cells, 5 Days




FIG. 17